Research and Markets: Competitor Analysis - Hepatitis Vaccines 2011

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/1f418e/competitor_analysi) has announced the addition of the "Competitor Analysis - Hepatitis Vaccines" report to their offering.

The present Competitive Intelligence report about Hepatitis Vaccines provides a competitor evaluation in the field of marketed and novel prophylactic vaccines against hepatitis A, hepatitis B, hepatitis A and B, hepatitis C and hepatitis E viruses. Product description considers use of adjuvants and preservatives. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently marketed vaccines and active projects in research and development for prophylaxis of hepatitis A, B, C and E. In addition, the report lists company-specific product portfolios and R&D pipelines of hepatitis vaccines on the market and in R&D. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Key Topics Covered:

  • Single Hepatitis A Virus Vaccines
  • Dual Hepatitis A and B Virus Vaccines
  • Single Hepatitis B Virus Vaccines
  • Combination Vaccines including HAV Vaccines
  • Combination Vaccines including HBV Vaccines
  • Hepatitis C Virus Vaccines
  • Hepatitis E Virus Vaccines
  • Corporate Hepatitis Vaccine Product Portfolios and R&D Pipelines

For more information visit http://www.researchandmarkets.com/research/1f418e/competitor_analysi



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.